

SMS Lifesciences India Limited

Registered & Corporate Office:

Plot No. 19-III, Road No. 71, Opp. Bharatiya Vidya Bhavan Public School,

Jubilee Hills, Hyderabad - 500 096. Telanagna, INDIA. Tel: +91-040-6628 8888. Fax: +91-40-2355 1401

CIN: L74930TG2006PLC050223 Email: info@smslife.in, www.smslife.in

To,

The Manager, Corporate Filings Department, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001

Security Code: 540679

Dear Sir/Madam,

Date: 17.09.2019

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Symbol: SMSLIFE

Subject: Update against news items on Ranitidine HCL.

This it to inform you that we have been manufacturing Ranitidine HCL (API) since 1990 and currently selling it to various markets except for USA (USDMF grade) and EU (CEP grade). Recently, USFDA and EMA have become aware of the presence of NDMA (N-Nitrosodimethylamine), a carcinogenic impurity, at low levels in some Ranitidine API products. USFDA in a statement on September 13th, informed that they are evaluating the presence of this impurity and the impact (if any) of this impurity on patients.

Since, we are one of the major manufacturers of Ranitidine API in the world, we are evaluating our Ranitidine product and its processes to ensure that our API is void of this NDMA impurity or are within permissible limits.

We currently foresee business as usual, but shall update you on any regulatory news/findings that can have a material impact on our business.

This is for your information and records.

Thanking you

Yours Faithfully

For SMS Lifesciences India Limited

Pavan Pise

Company Secretary